CZMWF News and Press, Carl Zeiss Meditec AG

2024-05-17 16:50:39 ET Summary Carl Zeiss Meditec has underperformed in the medtech field, but its long-term appeal remains intact. The company reported a decline in revenue and margins in the first half of 2023/2024, mainly due to challenges in the Chinese market. Despite nea...

2024-05-12 07:48:10 ET Carl Zeiss Meditec AG (CZMWF) Q2 2024 Earnings Conference Call May 08, 2024 04:30 AM ET Company Participants Sebastian Frericks - Head, IR Markus Weber - CEO Justus Wehmer - CFO Conference Call Participants Oliver Reinberg - Kep...

2024-05-10 12:03:06 ET More on STOXX Europe 600 Index: Dollar Is Softer Ahead Of The Employment Report Japan Drives Home Message Yen Retreats, While Stronger EMU GDP Underscores Nascent Recovery And Lifts The Euro Five reasons to prefer the European market vs...

2024-01-26 02:41:50 ET Summary Carl Zeiss Meditec has seen a significant increase in stock performance, up over 29% in less than 3 months. The company has shown strong top-line growth but a decline in EBIT and EBIT margin. Challenges include a decline in volume, unfavorable sa...

2023-12-19 13:00:57 ET More on Carl Zeiss Meditec AG, Carl Zeiss Meditec AG, etc. Carl Zeiss Meditec: Premiums Are Proven To Be Dicey In This Market Historical earnings data for Carl Zeiss Meditec AG Dividend scorecard for Carl Zeiss Meditec AG Financial info...

2023-10-24 03:32:23 ET Summary Carl Zeiss Meditec has seen a decline in its stock price, along with other high-valued companies, due to the commoditization of premium stocks. The company has impressive products, high gross margins, and strong financial performance compared to its ...

2023-08-08 05:13:37 ET Summary Carl Zeiss Meditech is a subsidiary of Carl Zeiss AG and manufactures tools for eye examination and medical lasers. The company has a strong financial performance with high gross and net margins. Despite being heavily focused on the German market...

2023-05-22 09:38:49 ET Summary Carl Zeiss falls short of expectations in H1, with its bottom line suffering steep declines in the face of several headwinds. While some of the H1 detractors are transitory, the lowered guidance points to structural headwinds as well, particularly on...

Summary Brent Saunders led Bausch + Lomb Corporation when it was sold to Valeant Pharmaceuticals. He later led and sold competitor Allergan to AbbVie. Brent Saunders likely signed on as CEO with the expectation of operating Bausch + Lomb Corporation as a fully standalone company. ...

Summary Carl Zeiss Meditec recorded strong order growth of 36% YoY in Q3 FY9/2022 results, highlighting strong underlying demand. Operating margins look stable at 20%, driven by an improving sales mix despite ongoing investment in R&D and marketing activities. The shares h...